Syneron Receives FDA Clearance for elos Plus Next Generation Multi-Platform Device

Syneron Medical Ltd. (NASDAQ: ELOS) announced today that it has received United States Food and Drug Administration (FDA) clearance for elos Plus™, a next generation multi-platform system featuring the Company's proprietary elos technology. The FDA clearance for elos Plus™ follows on the recent international launch in Europe and Asia.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.